Efficient funding of chemotherapy review - submissions on discussion paper

18 June 2021 - The efficient funding of chemotherapy review discussion paper was released on 21 May 2021 to gain ...

Read more →

Agenus announces U.S. FDA acceptance and priority review of balstilimab biologics license application for the treatment of recurrent or metastatic cervical cancer

17 June 2021 - Agenus today announced that the U.S. FDA has accepted Agenus’ biologics license application for balstilimab, an ...

Read more →

Expanded PBS listing to save Australians around $120,000 a year

17 June 2021 - More than 800 Australians with stage IV advanced or metastatic kidney cancer will now have improved access ...

Read more →

FDA approves avapritinib for advanced systemic mastocytosis

16 June 2021 - On June 16, 2021, the FDA approved avapritinib (Ayvakit, Blueprint Medicines) for adult patients with advanced ...

Read more →

Novartis prostate cancer drug receives U.S. FDA breakthrough designation

17 June 2021 - Swiss drugmaker Novartis has received breakthrough therapy designation from the U.S. FDA for an experimental treatment ...

Read more →

Istari Oncology announces FDA granted fast track designation to PVSRIPO for the treatment of advanced melanoma

14 June 2021 - Istari Oncology announced today the U.S. FDA has granted fast track designation to PVSRIPO for the ...

Read more →

Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients

14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...

Read more →

NICE to reassess Kyowa Kirin’s Poteligeo

14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...

Read more →

Delytact oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma

10 June 2021 - First oncolytic virus ever approved for treatment of malignant glioma or any primary brain cancer. ...

Read more →

Core patient reported outcomes in cancer clinical trials

9 June 2021 - This guidance provides recommendations to sponsors for collection of a core set of patient reported clinical outcomes ...

Read more →

Yuhan's Leclaza to be cheaper than AstraZeneca's Tagrisso

10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients ...

Read more →

Astellas’ Xtandi bags NICE approval in prostate cancer

10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...

Read more →

Copiktra (duvelisib) receives European Union marketing authorisation for the treatment of relapsed or refractory CLL and refractory FL

9 June 2021 - Secura Bio today announced that on 19 May 2021, the European Medicines Agency granted marketing authorisation for ...

Read more →

BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in microsatellite instability-high or mismatch repair-deficient solid tumours

7 June 2021 -BeiGene today announced that the Center for Drug Evaluation of the China NMPA has accepted a supplemental ...

Read more →

Alpha Tau receives breakthrough device designation from the FDA for Alpha DaRT

8 June 2021 - Alpha Tau Medical is pleased to announce that it has received a breakthrough device designation for Alpha ...

Read more →